REG - Oxford BioDynamics - PDMR Dealing / Grant of Share Options
23/10/2023 11:15
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231023:nRSW9802Qa&default-theme=true
RNS Number : 9802Q Oxford BioDynamics PLC 23 October 2023
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing / Grant of Share Options
23 October 2023 - Oxford BioDynamics Plc (AIM: OBD, the Company), a
biotechnology company developing precision medicine tests for immune health
based on the EpiSwitch® 3D genomics platform, announces that it has granted a
total of 2,500,500 options over its ordinary shares of 1 pence each
("Ordinary Shares"), to Group employees, including certain directors and PDMRs
of the Company, as outlined in the table below.
The options were granted under the Company's 2016 Employee Share Option Plan
with an exercise price of 34p per share, being the closing share price on 19
October 2023, the day immediately preceding the grant of the options. Prior to
the grant, Chief Financial Officer Paul Stockdale surrendered 50,000 share
options originally awarded in 2018.
The newly-granted options will vest in three equal tranches on the first,
second and third anniversaries of the date of grant. Vested options will
remain exercisable up to and including the tenth anniversary of the date of
grant.
Following this grant, the individuals referred to above hold options over
Ordinary Shares and are interested in Ordinary Shares as follows:
New options granted Total number of options over Ordinary Shares Ordinary Shares held
Number % of current issued share capital
Alexandre Akoulitchev, Chief Scientific Officer 250,000 1,596,131 6,603,082 3.26%
Paul Stockdale, Chief Financial Officer 250,000 1,050,000 331,818 0.23%
Matthew Wakefield, Non Executive Chairman 150,000 400,000 1,022,727 0.70%
David Holbrook, Non Executive Director 75,000 115,000 - -
David Blum, SVP of Marketing 250,000 462,500 75,000 0.04%
Thomas Guiel, Chief Operations Officer 250,000 650,000 365,000 0.25%
Ewan Hunter, Chief Data Officer 250,000 750,000 136,363 0.09%
The notifications below, made in accordance with the requirements of UK Market
Abuse Regulation, provide further details:
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Alexandre Akoulitchev
2 Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 250,000 ordinary shares at an exercise price of 34 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 20 October 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name David Blum
2 Reason for the notification
a) Position/status PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 250,000 ordinary shares at an exercise price of 34 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 20 October 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Thomas Guiel
2 Reason for the notification
a) Position/status PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 250,000 ordinary shares at an exercise price of 34 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 20 October 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name David Holbrook
2 Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 75,000 ordinary shares at an exercise price of 34 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 20 October 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Ewan Hunter
2 Reason for the notification
a) Position/status PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 250,000 ordinary shares at an exercise price of 34 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 20 October 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Paul Stockdale
2 Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Surrender and grant of share options
c) Price(s) and volume(s) Options over 50,000 ordinary shares at an exercise price of £1.70 per share
cancelled
Options over 250,000 ordinary shares at an exercise price of 34 pence per
share granted
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 19, 20 October 2023
f) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Matthew Wakefield
2 Reason for the notification
a) Position/status Director/PDMR
b) Initial notification/ Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Oxford BioDynamics Plc
b) LEI 2138005Y1TK258O5U928
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 1 pence each
Identification code
ISIN: GB00BD5H8572
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) 150,000 ordinary shares at an exercise price of 34 pence per share
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 20 October 2023
f) Place of the transaction Outside a trading venue
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 518910
Jon Burrows, CEO
Paul Stockdale, CFO
Shore Capital - Nominated Adviser and Broker Tel: +44 (0)20 7408 4090
Stephane Auton / Iain Sexton
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Rozi Morris OxfordBioDynamics@instinctif.com
Adam Loudon / Jack Kincade
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.
Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) and EpiSwitch® PSE
(http://www.94percent.com) (EpiSwitch Prostate Screening test) blood tests.
CiRT is a predictive immune response profile for immuno-oncology (IO)
checkpoint inhibitor treatments, launched in February 2022. PSE is a blood
test that boosts the predictive accuracy of a PSA test from 55% to 94% when
testing the presence or absence of prostate cancer, which has been launched in
the US and UK in September 2023.
In March 2021, the Company launched its first commercial prognostic test,
EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test) and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.
The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.
For more information, please visit the Company's website,
www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.
In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBXLFLXBLBFBVRecent news on Oxford Biodynamics
See all newsREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
AnnouncementREG - Oxford BioDynamics - Holding(s) in Company
Announcement